Epstein Secrets

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

ok at what I am up to, I have attached the full story. It is essentially the presentation I made in Moscow several years ago. I am now working with Russian Venture on the first, of what we both think will be a series of investments. As you can imagine, "the full story" is best told with a narrator, but maybe yo

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

ok at what I am up to, I have attached the full story. It is essentially the presentation I made in Moscow several years ago. I am now working with Russian Venture on the first, of what we both think will be a series of investments. As you can imagine, "the full story" is best told with a narrator, but maybe yo

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

ok at what I am up to, I have attached the full story. It is essentially the presentation I made in Moscow several years ago. I am now working with Russian Venture on the first, of what we both think will be a series of investments. As you can imagine, "the full story" is best told with a narrator, but maybe yo